Exploring RPSA as a biomarker for pancreatic cancer prognosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the role of ribosomal protein SA (RPSA) as a potential prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). It aims to analyze blood samples from patients treated at Reims University Hospital for resectable or potentially resectable pancreatic tumors, with or without prior chemotherapy. The study seeks to determine if RPSA expression correlates with tumor invasion and metastatic potential, addressing the current lack of effective biomarkers for PDAC prognosis.

Why it matters

Who can join: the full rules

inclusion criteria :

* Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy
* Adults (aged more than 18 years old)
* Patients who have signed the informed consent form

exclusion criteria :

* Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment).
* Minors
* Patients for whom PDAC is not the retained diagnosis

Where it's running

• Damien JOLLY
  Reims, France Recruiting

Study contacts

• Study coordinator: Jean-Baptiste OUDART
• Email: joudart@chu-reims.fr
• Phone: 03 10 73 62 87

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• KRAS Inhibitor ETX-929 in advanced solid tumors

  This trial tests ETX-929, alone or with cetuximab, in people whose cancers have KRAS mutations and have progressed after prior therapy.

  Recruiting Phase 1/2 Ensem Therapeutics · Fairfax, Virginia · NCT07912593

• Modified FOLFIRINOX with Pentamidine in Advanced Pancreatic Cancer

  This study tests whether adding pentamidine to a modified FOLFIRINOX regimen helps people with advanced or metastatic pancreatic cancer.

  Recruiting Phase 1 University of Oklahoma · Oklahoma City, Oklahoma · NCT07829185

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Reach and Engagement of Genetic Education, Risk Assessment, and Testing Feasibility (GENET) for PDAC risk

  This study tests whether online education plus a phone call from PanCAN helps Black, Latino/a, and Medicaid-enrolled people in Massachusetts learn about genetic and multi-cancer early detection testing and decide about getting tested.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07787156

• Imaging study of 203Pb-RMX-VH-PIB in GBM and PDAC patients

  This early-stage study tests a new imaging drug to see how it travels in the body and how much radiation different organs receive in adults with GBM or PDAC.

  Recruiting Phase 1 Radiomedix, Inc. · Houston, Texas · NCT07733674

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.